News

A Phase 1 clinical trial will evaluate the safety and tolerability of GLPG2737 as a possible treatment for cystic fibrosis (CF), Galapagos NV announced. CF is caused by mutations in the CFTR gene, which encodes a protein channel with the same name. When mutated, this protein can no longer transport chloride…

Several factors may worsen lung infections caused by the bacteria Staphylococcus aureus in cystic fibrosis (CF) patients, from bacterial load to co-infections, according to a new study. The study, “Factors Associated With Worse Lung Function In Cystic Fibrosis Patients With Persistent Staphylococcus aureus,” was published in the journal PLoS One.

A research team at Northwestern University has developed a flexible and wearable electronic device, which adheres to the skin, to measure sweat, monitor response to exercise, and detect the presence of certain biomarkers — all of which are relevant for conditions such as cystic fibrosis (CF). “Sweat is a rich, chemical…

People interested in knowing more about gene editing and its therapeutic applications can now download a document prepared by the American Society of Gene & Cell Therapy (ASGCT). The document, titled “Therapeutic Gene Editing: An ASGCT White Paper,” is intended as background information for policymakers, patients, and the general public…

A study evaluating the impact of palliative care on patients with serious diseases, such as cystic fibrosis (CF), and their caregivers, found it to improve patients’ quality of life and disease symptoms, and brought a sense of satisfaction to both patients and their caregivers. Palliative care, however, did not improve survival.

Cayston (aztreonam) was deemed the best treatment across a range of parameters in a study comparing inhaled antibiotic treatments against Pseudomonas  (P.) aeruginosa lung infections in patients with cystic fibrosis (CF). But the study also demonstrated that Quinsair (levofloxacin inhalation solution) came in as a good second, improving lung function better than…

Researchers have found that a “swimming”  movement by Pseudomonas aeruginosa, the bacteria most commonly associated with lung infections in cystic fibrosis (CF) patients, triggers an immune response against the pathogen, according to a new study. Its findings may help in targeting therapies to resolve lung infection in CF. The study, “Swimming Motility Mediates…

Blocking mucus absorption in the airways through the use of certain agents can strengthen an innate airway mechanism, called mucociliary clearance (MCC), that is often impaired in lung diseases such as cystic fibrosis (CF). The study, “Marked increases in mucociliary clearance produced by synergistic secretory agonists or inhibition of the epithelial sodium…

Children diagnosed with cystic fibrosis (CF) months after their birth have worse clinical outcomes than those diagnosed as newborns, a study reports. Its authors argue for improvements in CF diagnostic programs to detect these cases in infants as early as possible. The study, “Differences In Outcomes Between Early And Late Diagnosis Of Cystic Fibrosis…

Pharmaxis has entered into a research collaboration with the Woolcock Institute of Medical Research in Sydney, Australia, to develop an inhalation therapy that combines Pharmaxis’ Orbital Inhaler with a dry powder formulation of the antibiotic tobramycin. The resulting therapy is intended for patients with cystic fibrosis (CF).